Esophageal Mucormycosis  by Boatright, Benjamin et al.
Video Journal and Encyclopedia of GI Endoscopy (2014) 1, 658–660Available online at www.sciencedirect.com2212-0971& 2013 Th
http://dx.doi.org/1
☆☆The terms of th
nCorresponding au
fax: +1 601 984 454
E-mail addresses
stang@umc.edu (S.-
rwu@umc.edu (R. W
Fbhaijee@umc.edu (journal homepage: www.elsevier.com/locate/vjgienCLINICAL CASE REPORTSEsophageal Mucormycosis$$
Benjamin Boatrighta, Shou-jiang Tanga,n, Zebedee J. Whatley IVa,
Ruonan Wub, Julio Cespedesc, Feriyl BhaijeecaDivision of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center,
2500 North State Street, Jackson, MS 39216, USA
bDepartment of Radiology, University of Mississippi Medical Center, 2500 North State Street,
Jackson, MS 39216, USA
cDepartment of Pathology, University of Mississippi Medical Center, 2500 North State Street,
Jackson, MS 39216, USAReceived 16 April 2013; received in revised form 24 May 2013; accepted 30 May 2013KEYWORDS
Esophagus;
Mucor;
Mucormycosis;
Fungal infection;
Endoscopy;
Videoe Authors. Publis
0.1016/j.vjgien.20
is license also app
thor. Tel.: +1 601
8.
: bboatright@umc
j. Tang), jzwhatley
u), jCespedes@um
F. Bhaijee).Abstract
Mucormycosis is a rare invasive fungal infection with high mortality. It usually affects patients
with poorly controlled diabetes, immunosuppression, or hematological malignancies. Gastro-
enterologists need to be aware of this rare infection because endoscopy can facilitate early
diagnosis and prompt appropriate therapy. Here we describe a case of invasive esophageal
mucormycosis that developed in a 63-year-old man with diabetes, acute promyelocytic leukemia,
and prolonged leukopenia after chemotherapy. Upper endoscopy showed distal circumferential
esophageal wall thickening with devitalization. The mucosa did not bleed after endoscopic
biopsy. Histopathology conﬁrmed mucormycosis. He was treated with various antifungal agents
including echinocandins, ﬂuconazole, and liposomal amphotericin B. Despite aggressive
antifungal therapy and supportive care, the patient died 24 days later.
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1. Case report undA 63-year-old man with a previous history of diabetes,
hypertension. Received induction therapy with Daunorubicin, Cytarabine,
and Tretinoin for acute promyelocytic leukemia.er CC BY license.
659Esophageal Mucormycosis Subsequently he developed dysphagia, neutropenia, Candida
bacteremia, pericarditis, and acute renal failure. Upper endoscopy revealed normal mucosa in the prox-
imal esophagus. However, the distal esophagus showed
massive changes with circumferential wall thickening
and black discoloration due to devitalization. There
was no bleeding after endoscopic biopsy sampling and
devitalized ﬁbrous ﬁlaments remained at the biopsy site. Histological work-up of targeted biopsies showed necro-
tic tissue with numerous fungal organisms, consistent with
Candidiasis and mucormycosis with branching hyphae with
vascular invasion. He was treated with broad spectrum antibiotics and
various antifungal agents including echinocandins, ﬂuco-
nazole, and liposomal amphotericin B. Despite aggressive therapy and supportive care, the
patient died 24 days later.
2. Materials Diagnostic gastroscope (Olympus GIF-Q180, Olympus
America, Center Valley, PA).
3. Discussion
Zygomycoses are infections caused by fungi of the class
Zygomycetes and include two orders: Entomophthorales and
Mucorales [1–3]. Both are common fungi found in the soil
and in dying plants. Entomophthoromycosis is a subcuta-
neous and mucocutaneous infections that affects immuno-
competent hosts. Mucormycosis is an invasive infection that
affects immunocompromised hosts. The pre-disposing conditions
generally include uncontrolled diabetes, immunosuppression,
or chemotherapy. Although Mucormycosis is a rare it ranks
third behind Candidiasis and Aspergillosis. The hallmark of
mucormycosis is signiﬁcant angioinvasion with vessel throm-
bosis and tissue necrosis [1–3]. On histopathology, hyphae
can be observed growing in and around vessels. Direct
angioinvasion enhances hematogenous spread and results
in thrombosis, ischemia, and tissue necrosis.
Mucormycosis has been reported in the nasal sinuses, the
lungs, the gastrointestinal (GI) tract, and the kidneys.
Mortality varies with site of infection. In one large study,
disseminated disease had 96% mortality, GI tract infection
had 85% mortality, and pulmonary infection resulted in 76%
mortality [4].
GI mucormycosis is very rare [1–7]. The stomach, colon,
and ileum are the most commonly involved sites. Presenting
symptoms are either nonspeciﬁc, such as abdominal pain,
nausea and vomiting, or GI bleeding, or organ-speciﬁc.
The diagnosis is conﬁrmed by pathology: branching hyphae
with vascular invasion. Clinical management includes
systemic antifungal therapy and surgical debridement,
if possible, to remove all dead and infected tissue.
Mucormycosis has an extremely high death rate even when
aggressive therapy and surgical intervention is performed.
Because of the very high mortality rate despite aggressive
surgical and antifungal therapy, physicians and the patient
need to consider the operative risks in managing esopha-
geal mucormycosis.In conclusion, mucormycosis is a rare infection that occurs
predominantly in immunocompromised patients. It can affect
almost any part of the body and carries a high mortality rate.
Endoscopy can facilitate early diagnosis and appropriate med-
ical and surgical intervention.4. Scripted voiceoverVoiceover Text
A 63 year old man with diabetes and acute promyelocytic
leukemia was referred for dysphagia.
Recently, he underwent induction chemotherapy therapy
and developed neutropenia and Candida bacteremia.
CT scan of the chest revealed distal esophageal wall
thickening.
On upper endoscopy, black discoloration involves distal
esophagus associated with wall thickening and
devitalization.
The mucosa is intact but with luminal narrowing.
There is absence of bleeding after endoscopic biopsy.
Devitalized ﬁbrous ﬁlaments remain at the biopsy site.
The proximal esophagus appears normal.
Histopathology reveals necrotic tissues with numerous
fungal organisms, consistent with candidiasis and
Mucormycosis. Despite aggressive antifungal therapy
including amphotericin B, the patient died 24 days later.
Mucormycosis affects the immunocompromised hosts. This
invasive infection is associated with high mortality.
The hallmark of mucormycosis is signiﬁcant angioinvasion
with vessel thrombosis and tissue necrosis.
On histopathology, hyphae can be observed growing in and
around vessels.
Direct angioinvasion enhances hematogenous spread.
GI mucormycosis is very rare. The stomach, colon, and
ileum are the most commonly involved sites.
Mortality varies with site of infection. In one large study, GI
tract infection had 85% mortality.
Endoscopy can facilitate early diagnosis and appropriate
medical and surgical intervention.Funding source
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